Tandem Diabetes Care (Nasdaq:TNDM) announced real-world data confirming positive outcomes with its t:slim X2 insulin pump.
Data demonstrated that the t:slim X2 pump with Control-IQ advanced hybrid closed-loop technology resulted in immediate and ongoing improvements in glycemic control, quality of life outcomes and user-reported reduced burden of diabetes management.
According to a news release, the company presented the data yesterday at the Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Barcelona.
Much of Tandem’s data presented comes from its ongoing real-world evaluation of type 1 diabetes patients using t:slim X2 with Control-IQ — the Control-IQ Observational (CLIO) study. The analysis included data from 1,913 patients in the CLIO study who had at least nine months of experience using the technology, with glycemic metric relationships, patient ages and previous insulin delivery methods examined.
Tandem said the study demonstrated successful adoption of Control-IQ technology by people who previously utilized multiple daily injections (MDI) or other devices. The study also showed the efficacy of long-term use across all age cohorts, ranging from pediatrics to 65 years old and up, the company said.
Six-month data from 2,062 CLIO patients compared patient-reported outcomes before initiating and after half a year, demonstrating that Control-IQ users experienced improved quality of life, reduced diabetes burden and higher satisfaction with diabetes therapy irrespective of age, baseline HbA1c and previous insulin delivery method.
Apart from the CLIO study, researchers also retrospectively examined the first 90 days of pump activation in more than 17,500 MDI users transitioning to the t:slim X2 pump with Control-IQ. Results demonstrated that 95% of MDI users successfully initiated Control-IQ technology within 14 days of pump start, with all groups experiencing success with the technology. Tandem said that the group that delayed initiation the longest showed a lower time in range.
“Experience matters. And with more than 60 million real-world patient-use days in the United States, and even more globally, our Control-IQ technology continues to set the high bar in advanced automated insulin dosing,” Tandem VP and Medical Director Dr. Jordan Pinsker said in the release. “The data presented at ATTD further reinforces the strength of Control-IQ technology in both clinical- and patient-reported outcomes, and we are proud of the positive impact and increased freedom people report experiencing through the use of our technology solutions.”
